公开(公告)号：US10684284B2

公开(公告)日：2020-06-16

申请号：US15791354

申请日：2017-10-23

Applicant: INOVA DIAGNOSTICS, INC. ,  LEIDEN UNIVERSITY MEDICAL CENTER

Inventor： Michael Mahler ,  Leendert A. Trouw ,  Jan Wouter Drijfhout ,  Tom Huizinga ,  René Toes ,  Peter Van Veelen

IPC: G01N33/564 ,  C07K14/81 ,  C07K1/107

Abstract: The present disclosure relates to the field of molecular biology and more specifically to methods for detecting anti-carbamylated protein (anti-CarP) antibodies in the serum of rheumatoid arthritis (RA) patients.

公开(公告)号：US20180177891A1

公开(公告)日：2018-06-28

申请号：US15561935

申请日：2016-04-08

Applicant: Midatech Limited ,  University College Cardiff Consultants Limited ,  Nanopass Technologies LTD. ,  Leiden University Medical Center ,  Institut National De La Sante et de la Recherche Medicale

Inventor： Martina McAteer ,  Colin Mark Dayan ,  James Caradoc Birchall

IPC: A61K47/69 ,  A61P3/10 ,  A61K9/00 ,  A61K38/20 ,  A61P37/00 ,  A61K38/06 ,  A61K38/28 ,  A61K39/39 ,  A61K47/54 ,  A61K38/10 ,  A61K39/00

CPC classification number: A61K47/6923 ,  A61K9/0021 ,  A61K38/063 ,  A61K38/10 ,  A61K38/1841 ,  A61K38/2066 ,  A61K38/28 ,  A61K39/00 ,  A61K39/0008 ,  A61K39/39 ,  A61K47/542 ,  A61K47/549 ,  A61K47/6929 ,  A61K2039/54 ,  A61K2039/577 ,  A61P3/10 ,  A61P37/00 ,  C07K5/0215 ,  A61K2300/00

Abstract: The present invention provides a nano particle comprising: a core comprising metal atoms; a corona comprising a plurality of ligands covalently linked to the core, wherein said plurality of ligands comprises: at least one carbohydrate ligand; at least one glutathione ligand; and at least one autoantigen peptide ligand. Also provided are compositions and vaccines comprising the nanoparticles, methods for producing the nanoparticles and medical uses of the nanoparticles, including for antigen specific imunotherapy of an autoimmune disease, such as diabetes mellitus type 1, in a mammalian subject.

公开(公告)号：US20180038856A1

公开(公告)日：2018-02-08

申请号：US15791354

申请日：2017-10-23

Applicant: INOVA DIAGNOSTICS, INC. ,  LEIDEN UNIVERSITY MEDICAL CENTER

Inventor： Michael MAHLER ,  Leendert A. TROUW ,  Jan Wouter DRIJFHOUT ,  Tom HUIZINGA ,  René TOES ,  Peter VAN VEELEN

IPC: G01N33/564 ,  C07K1/107 ,  C07K14/81

Abstract: The present disclosure relates to the field of molecular biology and more specifically to methods for detecting anti-carbamylated protein (anti-CarP) antibodies in the serum of rheumatoid arthritis (RA) patients.

公开(公告)号：US20160281164A1

公开(公告)日：2016-09-29

申请号：US15005179

申请日：2016-01-25

Applicant: CELERA CORPORATION ,  LEIDEN UNIVERSITY MEDICAL CENTER (LUMC) Acting on Behalf of ACADEMIC HOSPITAL LEIDEN

Inventor： Lance Bare ,  James J. Devlin ,  Frits R. Rosendaal ,  Pieter H. Reitsma ,  Irene D. Bezemer

IPC: C12Q1/68 ,  G01N35/00

CPC classification number: C12Q1/6883 ,  A61K31/352 ,  A61K31/4365 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/60 ,  A61K31/715 ,  A61K31/727 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  C12Q2600/172 ,  G01N35/00

Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with venous thrombosis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

公开(公告)号：US20160250312A1

公开(公告)日：2016-09-01

申请号：US15028547

申请日：2014-10-13

Applicant: ISIS INNOVATION LIMITED ,  ACADEMISCH ZIEKENHUIS LEIDEN (ALSO ACTING UNDER THE NAME OF LEIDEN UNIVERSITY MEDICAL)

Inventor： Rhea Longley ,  Ahmed Salman ,  Alexandra Spencer ,  Adrian Hill ,  Chris Janse ,  Sahid Khan

IPC: A61K39/015 ,  C12N15/86 ,  C12N7/00 ,  C07K14/445 ,  C07K14/005

CPC classification number: A61K39/015 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/575 ,  C07K14/005 ,  C07K14/445 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/10021 ,  C12N2710/10022 ,  C12N2710/10023 ,  C12N2710/10034 ,  C12N2710/10043 ,  C12N2710/24021 ,  C12N2710/24022 ,  C12N2710/24023 ,  C12N2710/24034 ,  C12N2710/24043 ,  Y02A50/412

Abstract: The invention relates to an antigenic composition or vaccine comprising a viral vector, the viral vector comprising nucleic acid encoding Plasmodium protein PfLSA1, or a part or variant of Plasmodium protein PfLSA1; PfLSAP2, or a part or variant of Plasmodium protein PfLSAP2; PfUIS3, or a part or variant of Plasmodium protein PfUIS3; PfI0580c, or a part or variant of Plasmodium protein PfI0580c; and PfSPECT-1, or a part or variant of Plasmodium protein PfSPECT-1.

Abstract translation: 本发明涉及包含病毒载体的抗原组合物或疫苗，所述病毒载体包含编码疟原虫蛋白PfLSA1的核酸或疟原虫蛋白PfLSA1的部分或变体; PfLSAP2或疟原虫蛋白PfLSAP2的一部分或变体; PfUIS3或疟原虫蛋白PfUIS3的部分或变体; PfI0580c，或疟原虫蛋白PfI0580c的部分或变体; 和PfSPECT-1，或疟原虫蛋白PfSPECT-1的部分或变体。

公开(公告)号：US20150374734A1

公开(公告)日：2015-12-31

申请号：US14766913

申请日：2014-02-20

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  CENRE NATIONAL DE LA RECHERCHE SCIENTIFQUE (CNRS) ,  UNIVERSITE DE LILLE 2, UNIVERSITÉ DU DROIT ET DE LA SANTÉ ,  THE LEIDEN UNIVERSITY MEDICAL CENTER ,  INSTITUT PASTEUR DE LILLE

Inventor： Francois TROTTEIN ,  Christelle FAVEEUW ,  Elodie MACHO FERNANDEZ ,  Luis Javier CRUZ RICONDO

IPC: A61K31/7032 ,  C08G63/08 ,  A61K47/48

CPC classification number: A61K31/7032 ,  A61K31/7028 ,  A61K47/6843 ,  A61K47/6849 ,  A61K47/6937 ,  C08G63/08

Abstract: The present invention relates to particulate entity, such as a nanoparticle or conjugate, for use in particular as adjuvant in vaccine or immunotherapy. More specifically, the invention relates to a particulate entity comprising: iv. an iNKT cell agonist such as α Gal Car compound, and, v. one or more antigenic determinant(s) such as a tumour antigen(s) or pathogen-derived antigen(s), vi. a targeting agent that targets in vivo said iNKT cell agonist to dendritic cells, such as human BDCA3+ dendritic cells.

Abstract translation: 本发明涉及特别用作疫苗或免疫治疗中的佐剂的颗粒实体，例如纳米颗粒或缀合物。 更具体地，本发明涉及一种颗粒实体，包括：iv。 iNKT细胞激动剂如αGal Car化合物，和v。一种或多种抗原决定簇，例如肿瘤抗原或病原体衍生的抗原，vi。 靶向剂，其将体内所述iNKT细胞激动剂靶向树突细胞，例如人BDCA3 +树突状细胞。

公开(公告)号：US20150313988A1

公开(公告)日：2015-11-05

申请号：US14430674

申请日：2013-09-25

Applicant: LEIDEN UNIVERSITY MEDICAL CENTER ,  UNIVERSITY OF MANITORA

Inventor： Marjolein Kikkert ,  Paul Bertyne van Kasteren ,  Eric John Snijder ,  Brian Leonard Mark ,  Terrence William James

IPC: A61K39/12 ,  C12N7/00

CPC classification number: A61K39/12 ,  A61K39/02 ,  A61K39/40 ,  A61K39/42 ,  A61K2039/5254 ,  A61K2039/552 ,  C07K2299/00 ,  C12N7/00 ,  C12N2770/10021 ,  C12N2770/10034 ,  C12N2770/10062

Abstract: The present invention relates to replication-competent Arteriviruses having a decreased DUB/deISGylating activity due to a mutation in the PLP2 domain of the non-structural protein nsp2, to their use as a medicament, their use as a vaccine and in prophylaxis, to vaccines comprising such Arteriviruses and to Arteriviral PLP2-ubiquitin complexes.

Abstract translation: 本发明涉及由于非结构蛋白质nsp2的PLP2结构域中的突变而导致的DUB / deISGylating活性降低的复制型动态病毒，其作为药物的用途，它们作为疫苗的用途和预防疫苗 包括这种动脉病毒和动态病毒PLP2-泛素复合物。

公开(公告)号：US11077131B2

公开(公告)日：2021-08-03

申请号：US15776668

申请日：2016-11-17

Applicant: Academisch Ziekenhuis Leiden a/u Leiden University Medical Center

Inventor： Ronald Karel Louisa Van Brempt

IPC: A61K38/00 ,  A61K39/00 ,  A61K45/00 ,  A61K31/7088 ,  A61K38/17 ,  C12N15/113 ,  A61P9/00 ,  A61P11/00 ,  A61K45/06

Abstract: The disclosure is based on the finding that compounds capable of binding to (or interacting with) chromatin binding/remodelling complexes (for example Polycomb group PRC1 and Trithorax group MLL) and/or modulation of the same can be used to modulate (for example switch on/off) ciliogenesis as may occur, for example, in the human pulmonary bronchial epithelium. Provided are compounds, compositions, methods and medicaments which may be used to treat and/or prevent diseases and/or conditions associated with aberrant or defective ciliogenesis.

公开(公告)号：US20200230164A1

公开(公告)日：2020-07-23

申请号：US16751638

申请日：2020-01-24

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITE DE LILLE 2, UNIVERSITE DU DROIT ET DE LA SANTE ,  THE LEIDEN UNIVERSITY MEDICAL CENTER ,  INSTITUT PASTEUR DE LILLE

Inventor： Francois TROTTEIN ,  Christelle FAVEEUW ,  Elodie MACHO FERNANDEZ ,  Luis Javier CRUZ RICONDO

IPC: A61K31/7032 ,  C08G63/08 ,  A61K47/68 ,  A61K47/69 ,  A61K31/7028

Abstract: The present invention relates to particulate entity, such as a nanoparticle or conjugate, for use in particular as adjuvant in vaccine or immunotherapy. More specifically, the invention relates to a particulate entity comprising: iv. an iNKT cell agonist such as α Gal Car compound, and, v. one or more antigenic determinant(s) such as a tumour antigen(s) or pathogen-derived antigen(s), vi. a targeting agent that targets in vivo said iNKT cell agonist to dendritic cells, such as human BDCA3-dendritic cells.

公开(公告)号：US10583137B2

公开(公告)日：2020-03-10

申请号：US15778207

申请日：2016-12-02

Applicant: THE SCRIPPS RESEARCH INSTITUTE ,  LEIDEN UNIVERSITY

Inventor： Benjamin F. Cravatt ,  Daisuke Ogasawara ,  Andreu Viader ,  Hui Deng ,  Tom Van Der Wel ,  Marcelis Van Der Stelt

IPC: A61K31/496 ,  A61K31/454 ,  A61K31/4439 ,  A61K31/4192 ,  A61K31/506 ,  A61P25/28

Abstract: Provided herein are triazole compounds and pharmaceutical compositions comprising said compounds useful as modulators of DAGL(α) and DAGL(β). In some embodiments, the compounds described herein are selective DAGL(α) inhibitors. Furthermore, the subject compounds and compositions are useful for the treatment of neurodegenerative or neuroinflammatory disease.